Martens-Lobenhoffer Jens, Angermair Stefan, Bode-Böger Stefanie M
Institute of Clinical Pharmacology, Otto-von-Guericke University, Magdeburg, Germany.
Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Anesthesiology and Intensive Care Medicine, Campus Benjamin Franklin, Berlin,Germany.
J Chromatogr B Analyt Technol Biomed Life Sci. 2025 May 15;1258:124590. doi: 10.1016/j.jchromb.2025.124590. Epub 2025 Apr 9.
Dried blood spots (DBS) is a convenient method of blood sampling for biomedical quantification of various drugs. Compared to conventional venipuncture and subsequent plasma measurement, DBS provides advantages in less invasive sampling and easy and safe shipping of samples. The main drawback is the difficult calculation of precise plasma concentrations from the DBS measurements. In this study, a method for the quantification of the antimycotic drug isavuconazole from DBS was developed and its applicability in therapeutic drug monitoring (TDM) was evaluated by comparing the DBS quantification results with the corresponding plasma values. DBS were produced by spotting 15 μL of EDTA-blood onto DBS cards. The whole DBS spots were extracted in methanol:water 10:1, and the extracts were analyzed by an established HPLC method using fluorescence detection. Isavuconazole proved to be stable in DBS over 3 weeks at room temperature or refrigerated at 6 °C. Intra-day precision and accuracies of the quantification from DBS were better than 5 %, while the inter-day results were better than 12 %. Fourteen plasma samples from intensive care patients showing isavuconazole concentrations of <0.1 μg/mL to 3.52 μg/mL (median 1.42 μg/mL) were compared to the results obtained from corresponding DBS samples. All concentration values were covered by the calibration range (0.1-20 μg/mL) of the analytical method. Differences between plasma and DBS results were less than 0.2 μg/mL, with an underestimation of less than 6 % in the DBS values. As these differences were of no therapeutic relevance, DBS could be considered a viable matrix for TDM of isavuconazole in intensive care patients.
干血斑(DBS)是一种用于多种药物生物医学定量分析的便捷采血方法。与传统静脉穿刺及随后的血浆检测相比,DBS在采样侵入性较小以及样本运输简便安全方面具有优势。其主要缺点是难以根据DBS测量结果精确计算血浆浓度。在本研究中,开发了一种从DBS定量抗真菌药物艾沙康唑的方法,并通过将DBS定量结果与相应血浆值进行比较,评估了其在治疗药物监测(TDM)中的适用性。通过将15μL乙二胺四乙酸(EDTA)血滴在DBS卡上制备DBS。将整个DBS斑点在甲醇与水体积比为10:1的混合液中提取,提取物采用已建立的高效液相色谱(HPLC)荧光检测法进行分析。结果表明,艾沙康唑在室温下或6℃冷藏条件下于DBS中3周内保持稳定。日内DBS定量的精密度和准确度优于5%,日间结果优于12%。将14例重症监护患者的血浆样本(艾沙康唑浓度为<0.1μg/mL至3.52μg/mL,中位数为1.42μg/mL)与相应DBS样本的结果进行比较。所有浓度值均在分析方法的校准范围(0.1 - 20μg/mL)内。血浆和DBS结果之间的差异小于0.2μg/mL,DBS值的低估小于6%。由于这些差异不具有治疗相关性,DBS可被视为重症监护患者中艾沙康唑TDM的可行基质。